Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy Based on Database Data in Real-world Japanese Therapeutic Practice

Boehringer Ingelheim1 site in 1 countryJune 1, 2022

Interventionssubjects treated with telmisartan/hydrochlorothiazide Subjects treated with Telmisartan and amlodipine subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group subjects treated with telmisartan+amlodipine double pill

Drugssubjects treated with telmisartan/hydrochlorothiazide Subjects treated with Telmisartan and amlodipine subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group subjects treated with telmisartan+amlodipine double pill

Overview

Phase: Not Applicable
Intervention: subjects treated with telmisartan/hydrochlorothiazide
Conditions: Hypertension
Sponsor: Boehringer Ingelheim
Locations: 1
Primary Endpoint: Proportion of days covered of patients treated with single- and double- combination therapy
Status: Withdrawn
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

The primary objective of this study is to compare the medication adherence measured by PDC of patients with FDC or double-pill combination therapy in real-world Japanese therapeutic practice.The further objective of this study is how much influence the background of patients to the adherence.

Registry

clinicaltrials.gov

Start Date

June 1, 2022

End Date

July 11, 2022

Last Updated

3 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Boehringer Ingelheim

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patients with hypertension
•Patients must have their first prescription (defined as index date\*) for telmisartan and hydrochlorothiazide or Micombi® between 01/07/2010 and 28/09/2010
•Patients must have their first prescription (defined as index date\*) for telmisartan and amlodipine or Micamlo® between 10/12/2010 and 09/03/2011
•Patients must have at least 180 days follow up verified by the presence of prescription record

Exclusion Criteria

•Patients who were under 40 years old at the time of enrolment
•Patients who prescribed the study drugs less than 90 days during a follow up period of 180 days
•Patients whose visits are less than 2 times during a follow up period of 180 days